ACGA blogs published in January

2022-01-25

As part of ACGA advocacy efforts, we have been writing blogs on market trends and other CG issues. Check out our latest articles:

China: live and let VIE
A listing loophole used by tech firms such as Alibaba and Tencent to list overseas recently received a PRC regulatory stamp of approval. What is a VIE, why is it controversial and what does the future hold for these structures? Nana Li, China Research Director has some answers. Read more.

Corruption just got easier in Indonesia
Recent political machinations have emasculated Indonesia’s once-feared anti-corruption commission and its future looks bleak, writes Christopher Leahy, Research Director, Indonesia & the Philippines. Read more.

Taiwan: boardroom battle leaves shareholders bothered and bewildered
Lax disclosure regime keeps shareholders in the dark over power play at rare metals refiner. Neesha Wolf, Taiwan & Malaysia Research Director unpicks the antics to find a familiar CG foe at play. Read more.

Kangmei Pharmaceutical: China court dispenses strong medicine
Nana Li, China Research Director says Jackpot payout for shareholders in China’s inaugural class action sets the bar high for investor damages but is a bitter pill for independent directors. Read more.

Old school mentality in the new economy: Board diversity at the top 100 in Hong Kong
Jane Moir, Research Director for Hong Kong & Singapore reveals big tech underperforms while other firms make headway in elevating women to the C-Suite and nomination committee with promising results. Read more.

India nudges the elephant
Sharmila Gopinath, Research Director for India asks a question that Asian markets have been grappling with for two decades – can independent directors nominated by controlling shareholders, and essentially elected by them, be truly independent? India has some tentative answers. Read more.


Discover more on our blog page and follow us on LinkedIn and Twitter so that you won’t miss our timely updates on our articles, news and activities.